A Phase 3 interventional study of TAS-102 and Placebo in Colorectal Cancer, sponsored by Taiho Pharmaceutical Co., Ltd.. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-17.
Sponsored by Taiho Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. — 1 open to participants now, 1 under way, none of them phase 3. Colorectal Neoplasms · Otsuka Holdings Co., Ltd..
Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 11th registered.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. is open now, in 1 country. Recruiting first, the newest first:
Taiho Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 5
First in 1996; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 76 across 4,809 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 107 across the 13 interventional studies, 12 across the 1 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Taiho Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Taiho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 4 are open to participants now.
1 of the studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04999761Taiho Pharmaceutical Co., Ltd.AB122 Platform Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Colorectal Neoplasms by Otsuka Holdings Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
This is a multinational, double-blind, two-arm, parallel, randomized Phase 3 comparison study evaluating the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer. Patients will be randomly assigned (2:1) to TAS-102 (experimental arm) or placebo (control arm).
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TAS-102
Drug: Placebo
TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Overall Survival(OS)
The primary endpoint was Overall Survival (OS), which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.
Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Progression-free Survival (PFS)
Tumor assessments were performed throughout the study period and analyzed using Response Evaluation Criteria in Solid Tumors criteria (Version 1.1, 2009). Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment.
Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Time to Treatment Failure (TTF)
Time to treatment failure was defined as the time (in months) from the date of randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause. Censoring for TTF was also applied for those patients who were given non-study cancer treatment, with censoring at the time when the patient began the non-study cancer treatment.
Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria)
The assessment of ORR was based on Investigator review of the images according to RECIST Version 1.1. Overall response rate was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). At the analysis stage, the best overall response was assigned for each patient as the best response recorded from all responses recorded after study randomization. If applicable, responses recorded after disease progression or initiation of non-study cancer treatment was excluded. A patient's best response assignment of stable disease (SD) needed to be maintained for at least 6 weeks after study randomization. If a patient didn't meet this condition, best response was assigned "Not evaluable".
Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Disease Control Rate (DCR; CR, PR, or Stable Disease)
The assessment of DCR paralleled that of ORR, with DCR defined as the proportion of patients with objective evidence of CR, PR, or SD.
Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Duration of Response
Duration of response was derived for those patients with objective evidence of PR or CR. Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause. Patients alive and progression free as of the analysis cut-off date were censored at their last evaluable tumor response assessment prior to initiation of any non-study cancer treatment.
Time frame: From randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause, assessed up to 30 months.
Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Adverse Events)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
Time frame: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
Safety and Tolerability Evaluation Will Focus on Adverse Events and Laboratory Assessments(Laboratory Assessments)
All laboratory values that were out of the normal range were to be evaluated for their clinical significance before exposing the patient to the next dose of study medication. Any laboratory abnormality that was clinically significant, e.g., results in delay of study medication dosing, study discontinuation, required treatment due to abnormal values, or was considered by the Investigator to be medical important, were to be reported as an AE, unless it was considered part of clinical manifestations to a clinical diagnosis that has already been reported as an AE.
Time frame: From the time a patient signed informed until 30 day safety follow-up visit or until initiation of new anticancer treatment, or assessed up to 30 months.
Overall Survival(OS)(Wild Type KRAS)
The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by wild type KRAS.
Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Overall Survival(OS)(Mutant Type KRAS)
The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by mutant type KRAS.
Time frame: Every 8 weeks. Survival status should be collected for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met, whichever is later.
Progression-free Survival (PFS) (Wild Type KRAS)
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by wild type KRAS.
Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Progression-free Survival (PFS) (Mutant Type KRAS)
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by mutant type KRAS.
Time frame: Every 8 weeks. Tumor assessments will be performed until radiologic progression develops or the start of new anticancer treatment, for up to 12 months after the last patient is randomized or until the target number of events (deaths) is met.
Participants were enrolled at 406 centers in China, the Republic of Korea and Thailand from 16 October 2013 to 15 June 2015.
| Milestone | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Started | 271 | 135 |
| Completed | 271 | 135 |
| Not completed | 0 | 0 |
The primary endpoint was Overall Survival (OS), which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier.
| Months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Overall Survival(OS) | 7.8 (7.1 to 8.8) | 7.1 (5.9 to 8.2) |
Tumor assessments were performed throughout the study period and analyzed using Response Evaluation Criteria in Solid Tumors criteria (Version 1.1, 2009). Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment.
| Months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Progression-free Survival (PFS) | 2.0 (1.9 to 2.8) | 1.8 (1.7 to 1.8) |
Time to treatment failure was defined as the time (in months) from the date of randomization until the date of radiologic disease progression, permanent discontinuation of study treatment, or death due to any cause. Censoring for TTF was also applied for those patients who were given non-study cancer treatment, with censoring at the time when the patient began the non-study cancer treatment.
| months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Time to Treatment Failure (TTF) | 1.9 (1.9 to 2.2) | 1.8 (1.7 to 1.8) |
The assessment of ORR was based on Investigator review of the images according to RECIST Version 1.1. Overall response rate was defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR). At the analysis stage, the best overall response was assigned for each patient as the best response recorded from all responses recorded after study randomization. If applicable, responses recorded after disease progression or initiation of non-study cancer treatment was excluded. A patient's best response assignment of stable disease (SD) needed to be maintained for at least 6 weeks after study randomization. If a patient didn't meet this condition, best response was assigned "Not evaluable".
| percentage of participants | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Overall Response Rate (ORR; Complete Response [CR] or Partial Response [PR] Using RECIST Criteria) | 1.1 (0.2 to 3.3) | 0.0 (0.0 to 2.8) |
The assessment of DCR paralleled that of ORR, with DCR defined as the proportion of patients with objective evidence of CR, PR, or SD.
| percentage of participants | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Disease Control Rate (DCR; CR, PR, or Stable Disease) | 44.1 (37.9 to 50.3) | 14.6 (9.0 to 21.9) |
Duration of response was derived for those patients with objective evidence of PR or CR. Duration of response was defined as the time from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or to death due to any cause. Patients alive and progression free as of the analysis cut-off date were censored at their last evaluable tumor response assessment prior to initiation of any non-study cancer treatment.
| Months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Duration of Response | 6.6 (3.9 to 9.2) | 0 (0 to 0) |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
| Participants | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| No AEs | 2 | 15 |
| One or more AEs | 269 | 120 |
| One or more TEAEs | 269 | 118 |
| TEAE severity by CTCAE grade:Grade1 | 23 | 32 |
| TEAE severity by CTCAE grade:Grade2 | 84 | 41 |
| TEAE severity by CTCAE grade:Grade3 | 127 | 33 |
| TEAE severity by CTCAE grade:Grade4 | 30 | 11 |
| TEAE severity by CTCAE grade:Grade5 | 5 | 1 |
| TEAE causality(Related) | 244 | 70 |
| TEAE causality(Not Related) | 25 | 48 |
| One or more TEAEs leading to discontinuation | 27 | 13 |
| One or more SAEs | 63 | 32 |
| One or more TESAEs | 63 | 31 |
| One or more TEAEs leading to death | 5 | 1 |
All laboratory values that were out of the normal range were to be evaluated for their clinical significance before exposing the patient to the next dose of study medication. Any laboratory abnormality that was clinically significant, e.g., results in delay of study medication dosing, study discontinuation, required treatment due to abnormal values, or was considered by the Investigator to be medical important, were to be reported as an AE, unless it was considered part of clinical manifestations to a clinical diagnosis that has already been reported as an AE.
| Participants | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Anemia:Any Grade | 209 | 52 |
| Anemia:Grade >=3 | 48 | 8 |
| Leukopenia:Any Grade | 190 | 4 |
| Leukopenia:Grade >=3 | 56 | 0 |
| Neutropenia:Any Grade | 182 | 1 |
| Neutropenia:Grade >=3 | 90 | 0 |
| Lymphopenia:Any Grade | 146 | 34 |
| Lymphopenia:Grade >=3 | 39 | 3 |
| Thrombocytopenia:Any Grade | 96 | 10 |
| Thrombocytopenia:Grade >=3 | 8 | 2 |
| Lymphocytosis:Any Grade | 4 | 1 |
| Lymphocytosis:Grade >=3 | 1 | 0 |
| Increase in alkaline phosphatase level:Any Grade | 91 | 58 |
| Increase in alkaline phosphatase level:Grade >=3 | 11 | 5 |
| Hyperglycemia:Any Grade | 98 | 50 |
| Hyperglycemia:Grade >=3 | 7 | 3 |
| Increase in total bilirubin level:Any Grade | 99 | 28 |
| Increase in total bilirubin level:Grade >=3 | 19 | 10 |
| Hypoalbuminemia:Any Grade | 78 | 44 |
| Hypoalbuminemia:Grade >=3 | 8 | 0 |
| Hyponatremia:Any Grade | 81 | 38 |
| Hyponatremia:Grade >=3 | 12 | 6 |
| Hypocalcemia:Any Grade | 77 | 33 |
| Hypocalcemia:Grade >=3 | 3 | 1 |
| Increase in AST level:Any Grade | 63 | 40 |
| Increase in AST level:Grade >=3 | 10 | 7 |
| Increase in ALT level:Any Grade | 48 | 29 |
| Increase in ALT level:Grade >=3 | 3 | 4 |
| Hypokalemia:Any Grade | 31 | 11 |
| Hypokalemia:Grade >=3 | 2 | 1 |
| Increase in creatinine level:Any Grade | 13 | 10 |
| Increase in creatinine level:Grade >=3 | 3 | 0 |
| Hyperkalemia:Any Grade | 11 | 10 |
| Hyperkalemia:Grade >=3 | 1 | 0 |
| Hypercalcemia:Any Grade | 8 | 1 |
| Hypercalcemia:Grade >=3 | 0 | 1 |
The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by wild type KRAS.
| months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Overall Survival(OS)(Wild Type KRAS) | 8.6 (7.4 to 10.9) | 7.4 (5.6 to 9.2) |
The primary end point was OS, which was defined as the time from random assignment to the date of death. In the absence of confirmation of death or for patients alive at the OS cutoff date, survival time was censored at the date of last trial follow-up or the cutoff date, whichever was earlier. The OS indicated above as secondary outcome was analyzed by mutant type KRAS.
| months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Overall Survival(OS)(Mutant Type KRAS) | 7.0 (5.4 to 8.0) | 6.5 (4.6 to 7.6) |
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by wild type KRAS.
| months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Progression-free Survival (PFS) (Wild Type KRAS) | 2.0 (1.9 to 3.4) | 1.8 (1.7 to 1.8) |
Progression-free survival was defined as the time (in months) from the date of randomization until the date of the Investigator-assessed radiological disease progression or death due to any cause. Patients who received non-study cancer treatment before radiologic evidence of disease progression were censored at the date of the last evaluable tumor assessment before initiation of non-study cancer treatment. The PFS indicated above as secondary outcome was analyzed by mutant type KRAS.
| Months | TAS-102(Trifluridine/Tipiracil) | Placebo |
|---|---|---|
| Progression-free Survival (PFS) (Mutant Type KRAS) | 2.2 (1.9 to 3.4) | 1.8 (1.7 to 1.9) |
Collected over Safety monitoring continued from the time a patient signed informed until 30 days after the last dose of study medication or until the initiation of another cancer therapy, whichever came first, up to 30 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAS-102 | 205/271 (75.6%) | 63/271 (23.2%) | 269/271 (99.3%) |
| Placebo | 111/135 (82.2%) | 32/135 (23.7%) | 120/135 (88.9%) |
| Event | TAS-102 | Placebo |
|---|---|---|
| IleusGastrointestinal disorders | 2/271 | 4/135 |
| AscitesGastrointestinal disorders | 1/271 | 3/135 |
| AnaemiaBlood and lymphatic system disorders | 5/271 | 1/135 |
| Bile duct obstructionHepatobiliary disorders | 0/271 | 2/135 |
| PneumoniaInfections and infestations | 2/271 | 2/135 |
| Decreased appetiteMetabolism and nutrition disorders | 0/271 | 2/135 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/271 | 2/135 |
| Small intestinal obstructionGastrointestinal disorders | 4/271 | 1/135 |
| Intestinal obstructionGastrointestinal disorders | 3/271 | 1/135 |
| PyrexiaGeneral disorders | 3/271 | 0/135 |
| Event | TAS-102 | Placebo |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 124/271 | 27/135 |
| NauseaGastrointestinal disorders | 104/271 | 20/135 |
| White blood cell count decreasedInvestigations | 102/271 | 3/135 |
| NeutropeniaBlood and lymphatic system disorders | 98/271 | 2/135 |
| Decreased appetiteMetabolism and nutrition disorders | 81/271 | 22/135 |
| Neutrophil count decreasedInvestigations | 75/271 | 0/135 |
| FatigueGeneral disorders | 69/271 | 20/135 |
| VomitingGastrointestinal disorders | 60/271 | 13/135 |
| DiarrhoeaGastrointestinal disorders | 54/271 | 6/135 |
| Blood bilirubin increasedInvestigations | 53/271 | 12/135 |
| Age, Categorical(Participants) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 206 | 103 | 309 |
| >=65 years | 65 | 32 | 97 |
| Age, Continuous(years) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| Median | 58 (26 to 81) | 56 (24 to 80) | 57 (24 to 81) |
| Sex: Female, Male(Participants) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| Female | 101 | 51 | 152 |
| Male | 170 | 84 | 254 |
| Ethnicity (NIH/OMB)(Participants) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 271 | 134 | 405 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 271 | 135 | 406 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TAS-102(Trifluridine/Tipiracil) | Placebo | Total |
|---|---|---|---|
| South Korea | 55 | 26 | 81 |
| China | 204 | 101 | 305 |
| Thailand | 12 | 8 | 20 |
The record gives a start of Sep 2013, a primary completion of Feb 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taiho Pharmaceutical Co., Ltd. →